OXFORD, England, October 16 /PRNewswire/ -- Charles Macfarlane joins the Board of PharmaVentures as Non-Executive Director. PharmaVentures assists pharmaceutical and biotechnology companies worldwide in all aspects of deal making.
Fintan Walton, CEO of PharmaVentures says, “I am delighted to be welcoming such a high profile and experienced individual to the Board of PharmaVentures. Charles Macfarlane has sat as an advisor for the Board during the past year and his position as a Director will now provide the company with enormous experience as well as valuable contacts in the industry.”
Charles Macfarlane says, “PharmaVentures is a leading transactions company with whom I look forward to working at a key time in its growth.”
Charles’ career with the Procter & Gamble Company spans 40 years, culminating in Heading up the Alliance, Licensing and Acquisition activity of P&G in the Health Care Global Business Unit as Executive Director.
In London he was the founding Chairman of British American Business Inc’s. EU Trade and Investment Policy Committee and now serves as the head of the Policy Group. He is a member of the Board and Executive Committee of BABi.
Editor’s Notes
PharmaVentures (www.pharmaventures.com) is a leading results driven organisation assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. PharmaVentures provides tailored consulting services and the range of PharmaDeals intelligence products, helping our clients to drive greater value from their deals. PharmaVentures launched the world’s first pharmaceutical television show in May 2006 (www.pharmaventures.tv). Based in Oxford, UK the company employs over 30 people and has offices in the USA.
PharmaVentures Ltd
CONTACT: Gill Hall, Head of Marketing, email:enquiries@pharmaventures.com, +44-1865-784-177
